Jazz Pharmaceuticals beats by $0.26, misses on revenue

|About: Jazz Pharmaceuticals, Inc. (JAZZ)|By:, SA News Editor

Jazz Pharmaceuticals (NASDAQ:JAZZ): Q3 Non-GAAP EPS of $3.58 beats by $0.26; GAAP EPS of $2.41 beats by $0.41.

Revenue of $469.4M (+14.0% Y/Y) misses by $13.25M.

Press Release

Subscribe for full text news in your inbox